Articles Archives
05/01/2025
New Article with Contract Pharma: Minimizing Capital Expenditures through Supply Chain Integration
Cryoport Systems has been featured in a new Contract Pharma article, “Minimizing Capital Expenditures through Supply Chain Integration.” This article explores how an integrated supply chain partner like Cryoport Systems helps organizations reduce risk, preserve capital, and gain the flexibility to scale without the burden of building it all themselves.
03/21/2025
Strengthening ATMP Development in Europe: How BioServices Centers in France Enable Efficiency and Scalability
As Advanced Therapy Medicinal Product (ATMP) developers progress from early-stage research to late-phase clinical trials and commercialization, biostorage, sample management, and regulatory-compliant logistics become increasingly complex. Efficiently managing these critical components is essential to ensure product integrity, regulatory compliance, and seamless supply chain operations.
02/04/2025
World Cancer Day: Advancing the Fight with Cell and Gene Therapies
Each year on World Cancer Day, the global community comes together to raise awareness, encourage prevention, and support those affected by cancer. It is a day of reflection, a time to recognize the immense progress that has been made in cancer research while acknowledging the work that still lies ahead.
08/26/2024
3 Fundamental Services for Superior Master Cell Bank Management
The consistency of controlled conditions is vital throughout every step in producing advanced therapies, and the process usually begins with the secure handling and storage of the cells used for manufacturing.
06/27/2024
Cryoport Systems Celebrates Expanded French Facility with Ribbon Cutting Ceremony
Cryoport Systems commemorated the significant expansion of its Pont-du-Château facility in France with a ribbon cutting ceremony that officially launched the updated site.
04/16/2024
Overcoming Industry Obstacles for Cell and Gene Therapy Development
In the rapidly advancing world of cell and gene therapy (CGT) development, finding the proper solution to overcome common industry obstacles is a challenge that can impact entire production timelines.
02/22/2024
Examining 2023 & 2024: What’s to Come with President & CEO, Mark Sawicki
The cell and gene therapy industry is poised for many changes in 2024. With persistent challenges facing manufacturers and developers such as the retention of experienced talent or a general lack of funding for specialized therapies, the state of what’s to come feels more unsure than it has in recent years.
07/26/2023
